Your browser doesn't support javascript.
loading
Cost-effectiveness of colorectal cancer screening in Slovakia.
Babela, Robert; Orsagh, Andrej; Ricova, Jana; Lansdorp-Vogelaar, Iris; Csanadi, Marcell; De Koning, Harry; Reckova, Maria.
Afiliação
  • Babela R; National Oncology Institute, Bratislava & Biomedical Research Centre for the Slovak Academy of Sciences.
  • Orsagh A; Department of Gastroenterology, National Oncology Institute, Bratislava & National Cancer Institute, Bratislava, Slovakia.
  • Ricova J; National Oncology Institute, Bratislava & Biomedical Research Centre for the Slovak Academy of Sciences.
  • Lansdorp-Vogelaar I; Department of Public Health, Erasmus MC University Medical Center Rotterdam, the Netherlands.
  • Csanadi M; Syreon Research Institute, Budapest, Hungary.
  • De Koning H; Department of Public Health, Erasmus MC University Medical Center Rotterdam, the Netherlands.
  • Reckova M; National Oncology Institute, Bratislava & Biomedical Research Centre for the Slovak Academy of Sciences.
Eur J Cancer Prev ; 31(5): 415-421, 2022 09 01.
Article em En | MEDLINE | ID: mdl-34789653
ABSTRACT

BACKGROUND:

Colorectal cancer (CRC) is an ideal disease for screening due to known and detectable precursor lesions and slow progression from benign adenoma to invasive cancer. The introduction of organized population-based screening programs reduces the burden of colorectal cancer and increases the quality of the screening process with a more favorable harm to benefit ratio compared to opportunistic screening.

METHODS:

The study used the microsimulation screening analysis-colon simulation model for the estimation of the effect of various factors on cancer incidence and mortality. The model simulated the Slovakian population from 2018 to 2050. Study includes the analysis of two screening strategies the fecal immunochemical test (FIT) every 2 years and annual FIT. Cost-effectiveness parameters were evaluated comparing each simulated screening scenario with no screening.

RESULTS:

Compared to no screening, the biennial FIT would detect 29 600 CRC cases and annual FIT 37 800 CRC cases. Mortality due to CRC showed benefits for both strategies with 17,38% reduction in biennial FIT and 24,67% reduction in annual FIT approach. Both screening programs were more costly as well as more effective compared to no screening. The ICER for biennial FIT strategy was 1776 EUR per 1 QALY and for the annual FIT 3991 EUR per 1 QALY.

CONCLUSIONS:

In summary, this is the first cost-effectiveness analysis focusing on multiple national CRC screening strategies in Slovakia. Both strategies demonstrated cost-effectiveness compared to no screening. However, for optimal population-based programmatic screening strategy, the policymakers should also consider human resources availability, acceptability of screening test among the population or additional resources including the screening funding.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Detecção Precoce de Câncer Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies / Screening_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Eur J Cancer Prev Assunto da revista: NEOPLASIAS / SAUDE PUBLICA Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Detecção Precoce de Câncer Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies / Screening_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Eur J Cancer Prev Assunto da revista: NEOPLASIAS / SAUDE PUBLICA Ano de publicação: 2022 Tipo de documento: Article